Our portfolio of anti-TNF therapies are marketed in the European Union. TNF inhibitors are a type of therapy to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), ankylosing spondylitis, and psoriasis. They reduce inflammation and reduce disease progression by targeting an inflammation-causing substance called Tumor Necrosis Factor (TNF).

These therapies are biosimilars, referencing originator products already available. By bridging our heritage of scientific innovation with an opportunity to reduce healthcare costs and increase access to biologics, developing biosimilars is a compelling way in which we can make a difference in the lives of the patients we serve.



Biosimilars are highly similar versions of already licensed molecules (known as originators). Having successfully delivered complex originator biologics for approximately 40 years, today Biogen is one of only a handful of companies with the manufacturing capabilities and the deep scientific expertise needed to produce biosimilars of advanced biologics.

As many biologics reach the end of their patent lives, Biogen believes biosimilars are central to safeguarding future healthcare innovation. Biosimilars can alleviate some of the burden on healthcare systems by offering cost savings and promoting sustainable access to therapies. Biosimilars can also expand options for patients and physicians to meet individual needs. Biogen has the expertise to manufacture and reliably supply biosimilars. Our biosimilars are manufactured in state of the art facilities in Denmark and South Korea.



Biogen 122331 V2  Date of Preparation: June 2023